Immunoassays using different primary antibodies, assay formats, and scoring approaches have been reported to assess the prevalence of PD‐L1 positivity and the efficacy of treatment in NSCLC.9, 10, 11, 12, 17, 18. Here, CD274 is linked to non-small cell lung carcinoma.